BoJ’s Ueda: Japan's economy recovering moderately albeit with some weaknesses
Bank of Japan (BoJ) Governor Kazuo Ueda said on Tuesday that the Japanese economy is recovering moderately albeit with some weaknesses. Ueda added that price trend is approaching 2%.
Key quotes
Japan's economy recovering moderately albeit with some weaknesses.
September tankan showed business sentiment in good shape.
Underlying inflation approaching 2%.
Economy, prices moving in line with our baseline forecasts.
Financial conditions are accommodative.
Even after September rate hike, accommodative financial conditions continue to support economic activity.
Will continue to raise policy rate in accordance with economic, price, financial developments.
Pace and timing of future policy adjustment will be decided based on likelihood of our baseline projections materialising as well as risks.
Important to anchor underlying inflation around 2%.
Market reaction
At the time of writing, the USD/JPY pair is up 0.18% on the day at 158.20.
Ueda keeps BoJ on gradual tightening path as Yen focus stays on inflation
FXS Speechtracker scores the speech at 7.2, exactly in line with Ueda’s historic average, signaling a consistent policy tone rather than a surprise shift. The emphasis on the economy “recovering moderately,” favorable business sentiment, and accommodative financial conditions, even after the September rate hike, points to a mildly hawkish bias, as BoJ remains committed to further gradual rate increases while avoiding aggressive tightening.
By stressing that underlying inflation is approaching 2% and that economy and prices are moving in line with baseline forecasts, Ueda reinforces confidence that BoJ is on track toward the inflation target, which supports a constructive backdrop for the Yen. The pledge to “continue to raise policy rate” in accordance with economic, price, and financial developments, and the importance of anchoring inflation around 2%, underpins expectations of a slow but ongoing normalization, likely offering medium-term support to the Yen while limiting immediate volatility.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Bank of England's most hawkish official: The labor market is "stationary" rather than loose, and inflation is deeply entrenched.
The Bank of England hawkish official Mann stated that the labor market is "static" rather than loose, and warned that inflation is deeply entrenched; rising fuel and energy prices may cause inflation to "significantly exceed 4%" early next year.
BUZZ - Bank of America gives Diodes a "Buy" rating, driving its stock price up
October 6 - Semiconductor product manufacturer Diodes (DIOD.O) saw its stock price rise 3.38% in pre-market trading to $107.64. BofA has initiated coverage of DIOD with a “Buy” rating and a price target of $135, implying about 30% upside from the previous closing price. According to the report, DIOD holds a favorable position in the automotive, industrial, and AI data center semiconductor markets, positioning it to expand its market share. The increasing use of semiconductors in automobiles and growing demand for AI infrastructure are expected to drive the company’s long-term growth. The firm anticipates that DIOD’s AI data center business—which currently accounts for about 12% of total revenue—could triple by 2030. As of the previous trading day’s close, the stock’s year-to-date growth has already more than doubled. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translations may contain errors or lack context and are provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses resulting from the use of automated translation features.)
BUZZ-BridgeBio shares rise as FDA initiates priority review for dwarfism drug
On October 6th, shares of pharmaceutical company BridgeBio Pharma (BBIO.O) rose 2.5% in pre-market trading to $67.80. The company announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking approval for the investigational oral drug infigratinib for the treatment of children with achondroplasia, the most common type of dwarfism. The FDA has set a target decision date of February 4, 2027. The application is based on a late-stage clinical trial that met both primary and key secondary endpoints; children treated with infigratinib experienced an adjusted annual growth velocity 1.74 centimeters greater than those given placebo. The drug also improved arm span and body proportions in children under eight years old. No serious adverse events or discontinuations related to the drug were reported. BridgeBio plans to apply for European approval in the fourth quarter of 2026. As of the close of the previous trading day, BBIO shares are down 13.5% year-to-date. (For the convenience of non-English speakers, Reuters has automated this report into several other languages. Because automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translation, which is provided for readers’ convenience only. Reuters accepts no liability for any damages or losses arising from the use of automated translation.)
Google (GOOGL.US) spends $4.3 billions on electricity, securing 3,590 megawatts of long-term energy from Constellation Energy (CEG.US).
Google has signed a 3,590 MW power purchase agreement with Constellation Energy, with a quarter of the electricity coming from nuclear power, involving an investment of $4.3 billion.
